Strategic partnership TheraVectys operates a joint-laboratory model with the Institut Pasteur, highlighting a readiness for collaborative research programs and co-developed vaccine/immunotherapy candidates that can be jointly commercialized or licensed to industry partners.

Lentiviral platform The company’s proprietary lentiviral vector technology positions it as a specialist in immunotherapies and vaccine candidates, suggesting sales opportunities with biotech firms seeking advanced delivery platforms or collaboration in preclinical/clinical development.

Global footprint With bases in Paris and the USA and a focus on immunotherapy, TheraVectys can offer cross-border R&D collaboration, technology transfer, and multinational clinical development support to global pharma and biotech sponsors.

Funding indicate Recent funding of 20 million USD and a total funding of 51 million USD signal investor validation and potential for strategic partnerships, licensing deals, or milestone-driven collaborations to accelerate pipeline programs.

Market positioning A niche biotech with modest revenue but high specialization in vaccine and immunotherapy platforms positions TheraVectys as a partner for early-stage programs, translational research collaborations, and contracted research in virology and immune modulation.